Upcoming event

Essential research priorities in renal cancer: a modified delphi consensus statement

European Urology Focus, September 2021

Predicting intra‐operative and postoperative consequential events using machine‐learning techniques in patients undergoing robot‐assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study

BJU International, April 2021

Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry

Journal of Urology, December 2020

Updated European Association of Urology guidelines on renal cell carcinoma: Nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma

European Urology, December 2020

Molecular subtypes of fully resected clear cell renal cell carcinoma are prognostic for risk of relapse and may impact adjuvant treatment

Management and survival of patients with retroperitoneal recurrences following radical nephrectomy: Results from a multi-institutional international datasets

Surgical management and outcomes of renal tumors arising from horseshoe kidneys: results from an international multicenter collaboration

European Urology, September 2020

The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium

European Urology Oncology, November 2020

Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy

Cancer, September 2020

Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)

Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing

Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

PreviousNext